Literature DB >> 9486405

HLA class II phenotype controls diversification of the autoantibody response in primary Sjögren's syndrome (pSS).

M Rischmueller1, S Lester, Z Chen, G Champion, R Van Den Berg, R Beer, T Coates, J McCluskey, T Gordon.   

Abstract

The coexistence of anti-La (SS-B) and anti-Ro (SS-A) autoantibodies in pSS is probably explained by intermolecular spreading of autoimmunity toward different components of the La/Ro ribonucleoprotein (RNP). In order to evaluate the role of the HLA class II phenotype in controlling diversification of this autoantibody response, 80 patients with pSS were typed by polymerase chain reaction sequence-specific oligonucleotide (PCR-SSO) at the HLA class II loci DRB1, DQA1 and DQB1. Serum samples were examined for anti-La and anti-Ro by counterimmunoelectrophoresis and by ELISA using purified recombinant La and 60-kD Ro proteins. Patient sera were classified according to the extent of diversification of the anti-La, anti-Ro response including the presence or absence of precipitating anti-La antibodies. Immunogenic characteristics of these stratified groups were then studied. All patients with pSS, with or without autoantibodies to Ro and La, were found to have at least one of the HLA-DRB1 types DR2, DR3 or DR5. The HLA DR3-DQA1*0501-DQB1*02 (DR3-DQ2) haplotype was primarily associated with a diversified La/Ro RNP response containing precipitating autoantibodies to La (P<0.001); whereas the haplotype HLA DR2-DQA1*0102-DQB1*0602 (DR2-DQ1) was associated with a less diversified La/Ro RNP response containing non-precipitating (restricted epitope) anti-La autoantibodies (P<0.001). Anti-La-positive patients lacking both HLA-DR2 and HLA-DR3 all expressed the HLA-DQA1*0501 allele, which was present at increasing frequency with greater diversification of the anti-La/Ro autoantibody response. The association of distinct HLA haplotypes with different degrees of autoantibody diversification in patients with pSS suggests a model of HLA-restricted presentation of La/Ro peptide determinants to autoreactive helper T cells. We propose that non-precipitating anti-La responses are driven by limited intermolecular help from DR2-DQ1-restricted T helper cells recognizing Ro determinants. On the other hand, we speculate that the more diversified, precipitating anti-La responses obtain more efficient cognate T help from DR3-DQ2-restricted T helper cells recognizing La determinants, where HLA-DQA1*0501 may be a critical determinant for antigen presentation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486405      PMCID: PMC1904917          DOI: 10.1046/j.1365-2249.1998.00504.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Restricted epitope recognition by precipitin-negative anti-La/SS-B-positive sera.

Authors:  T Gordon; C Mavrangelos; J McCluskey
Journal:  Arthritis Rheum       Date:  1992-06

Review 2.  Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology.

Authors:  E M Tan
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

4.  Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus. Correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody.

Authors:  R G Hamilton; J B Harley; W B Bias; M Roebber; M Reichlin; M C Hochberg; F C Arnett
Journal:  Arthritis Rheum       Date:  1988-04

5.  The immune response to 52-kDa Ro and 60-kDa Ro is linked in experimental autoimmunity.

Authors:  C L Keech; T P Gordon; J McCluskey
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

6.  Interrelationships of HLA-DR, MB, and MT phenotypes, autoantibody expression, and clinical features in systemic lupus erythematosus.

Authors:  J M Ahearn; T T Provost; C A Dorsch; M B Stevens; W B Bias; F C Arnett
Journal:  Arthritis Rheum       Date:  1982-09

7.  HLA antigens in Italian patients with systemic lupus erythematosus: evidence for the association of DQw2 with the autoantibody response to extractable nuclear antigens.

Authors:  P Lulli; G D Sebastiani; S Trabace; G Passiu; S Cappellacci; F Porzio; M Morellini; F Cutrupi; M Galeazzi
Journal:  Clin Exp Rheumatol       Date:  1991 Sep-Oct       Impact factor: 4.473

8.  Distinct immunologic features of Finnish Sjögren's syndrome patients with HLA alleles DRB1*0301, DQA1*0501, and DQB1*0201. Alterations in circulating T cell receptor gamma/delta subsets.

Authors:  T O Kerttula; P Collin; A Polvi; M Korpela; J Partanen; M Mäki
Journal:  Arthritis Rheum       Date:  1996-10

9.  HLA-alloantigen associations in Greek patients with Sjögren's syndrome.

Authors:  C A Papasteriades; F N Skopouli; A A Drosos; A P Andonopoulos; H M Moutsopoulos
Journal:  J Autoimmun       Date:  1988-02       Impact factor: 7.094

10.  Sjögren's syndrome association with HLA-Dw3.

Authors:  T M Chused; S S Kassan; G Opelz; H M Moutsopoulos; P I Terasaki
Journal:  N Engl J Med       Date:  1977-04-21       Impact factor: 91.245

View more
  19 in total

Review 1.  Immunopathogenesis of Sjögren's syndrome.

Authors:  Andrea T Borchers; Stanley M Naguwa; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

2.  Molecular chaperones are targets of autoimmunity in Ro(SS-A) immune mice.

Authors:  G Kinoshita; A W Purcell; C L Keech; A D Farris; J McCluskey; T P Gordon
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

3.  M3 muscarinic acetylcholine receptor-reactive Th17 cells in primary Sjögren's syndrome.

Authors:  Saori Abe; Hiroto Tsuboi; Hanae Kudo; Hiromitsu Asashima; Yuko Ono; Fumika Honda; Hiroyuki Takahashi; Mizuki Yagishita; Shinya Hagiwara; Yuya Kondo; Isao Matsumoto; Takayuki Sumida
Journal:  JCI Insight       Date:  2020-08-06

4.  High-resolution HLA analysis of primary and secondary Sjögren's syndrome: a common immunogenetic background in Mexican patients.

Authors:  Gabriela Hernández-Molina; Gilberto Vargas-Alarcón; Jose M Rodríguez-Pérez; Nancy Martínez-Rodríguez; Guadalupe Lima; Jorge Sánchez-Guerrero
Journal:  Rheumatol Int       Date:  2014-09-28       Impact factor: 2.631

Review 5.  Update on Pathogenesis of Sjogren's Syndrome.

Authors:  Pulukool Sandhya; Biji Theyilamannil Kurien; Debashish Danda; Robert Hal Scofield
Journal:  Curr Rheumatol Rev       Date:  2017

Review 6.  Genetics of Sjögren's syndrome.

Authors:  Leyla Y Teos; Ilias Alevizos
Journal:  Clin Immunol       Date:  2017-05-03       Impact factor: 3.969

7.  MHC class II, tumour necrosis factor alpha, and lymphotoxin alpha gene haplotype associations with serological subsets of systemic lupus erythematosus.

Authors:  N J McHugh; P Owen; B Cox; J Dunphy; K Welsh
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

Review 8.  Genes and Sjögren's syndrome.

Authors:  Beth L Cobb; Christopher J Lessard; John B Harley; Kathy L Moser
Journal:  Rheum Dis Clin North Am       Date:  2008-11       Impact factor: 2.670

9.  Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study.

Authors:  A G Tzioufas; R Wassmuth; U G Dafni; A Guialis; H-J Haga; D A Isenberg; R Jonsson; J R Kalden; H Kiener; C Sakarellos; J S Smolen; N Sutcliffe; C Vitali; E Yiannaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2002-05       Impact factor: 19.103

10.  Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome.

Authors:  Jacques-Eric Gottenberg; Nicolas Cagnard; Carlo Lucchesi; Franck Letourneur; Sylvie Mistou; Thierry Lazure; Sebastien Jacques; Nathalie Ba; Marc Ittah; Christine Lepajolec; Marc Labetoulle; Marc Ardizzone; Jean Sibilia; Catherine Fournier; Gilles Chiocchia; Xavier Mariette
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.